Trials / Completed
CompletedNCT05560555
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
Tafamidis 61mg, Outcomes in ATTR Amyloidosis With Neurologic and Multisystemic Involvement - TRAMA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of patients with hereditary transthyretin amyloidosis (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt) that have been enrolled in B3461028 and B3461045 studies in Spain - exposed to tafamidis 61mg for ≥12 months with polyneuropathy (PN) have kept going to their multisystemic follow-ups (neuro/ophthalmo/gastrointestinal) ≥12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafamidis | 61 milligrams (mg) as received in studies B3461028 and B3461045 |
Timeline
- Start date
- 2022-10-24
- Primary completion
- 2022-11-15
- Completion
- 2022-11-15
- First posted
- 2022-09-29
- Last updated
- 2024-05-13
- Results posted
- 2024-05-13
Locations
3 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT05560555. Inclusion in this directory is not an endorsement.